Assessment of severity and quality of life in chronic urticaria

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 2, 2014, Pages 80-86

  Jáuregui Presa, Ignacio ^a   Ortiz de Frutos, F J ^b   Ferrer, M ^c   Gimenez Arnau A ^d   Sastre, J ^e   Bartra, J ^h   Labrador, M ^f   Silvestre, J F ^g   Valero, A ^h  

^a HOSPITAL DE BASURTO   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Grupo de Trabajo Ecografía SoMaMFyC   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic urticaria; Chronic Urticaria Quality of Life Questionnaire (CU Q2oL); Dermatology Life Quality Index (DLQI); Itch Intensity Scale; Medical Outcome Study 36 Item Sort Form Health Survey (SF 36); Nottingham Health Profile (NHP); Satisfaction Profile (SAT P); Skindex 29; Urticaria Activity Score (UAS); Urticaria Severity Score (USS); Visual analog scale (VAS); VQ Dermato; Work Productivity and Activity Impairment (WPAI); World Health Organization Quality of Life Assessment Brief (WHOQOL BREF)

Indexed keywords

ANTIHISTAMINIC AGENT;

CHRONIC URTICARIA; CHRONIC URTICARIA QUALITY OF LIFE QUESTIONNAIRE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; HUMAN; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NOTTINGHAM HEALTH PROFILE; PATIENT SATISFACTION; PREVALENCE; QUALITY OF LIFE; REVIEW; SHORT FORM 36; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME; URTICARIA ACTIVITY SCORE; URTICARIA SEVERITY SCORE; VISUAL ANALOG SCALE;

CHRONIC DISEASE; HUMANS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; URTICARIA;

EID: 84901932829     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Grattan C. Chronic urticaria: General Principles and Management. In: Greaves MW, Kaplan AP, eds. Urticaria and Angioedema. New York: Marcel Dekker, 2004:343-68.
2. Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipía S, García AbujetaJL, Gonzalo MA, Lleonart R, Martínez Cócera C, Rodríguez A, Ferrer M.: Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol. 2004;14:214-20.
3. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CEH, Kapp A, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B, Maurer M. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417-26.
4. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CEH, Kapp A, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B, Maurer M. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy. 2009;64:1427-43.
5. Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63:777-80.
6. Daudén E, Sánchez-Perez J, Prieto M, Roset M. Validación de la versión española de la escala de intensidad del picor (Cuestionario Itch Severity Scale, ISS). Estudio PSEDA. Actas Dermosifiliogr. 2011;102:527-36.
7. Colás C, de la Hoz B, Rodríguez M, Roger A. Calidad de vida en las enfermedades alérgicas. En "Tratado de Alergología" ed. por Peláez A-Dávila IJ. Tomo 2, Capítulo 82:1709-34.
8. Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, Braga M, Lombardi C, Fassio O, Canonica GW. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy. 2005;60:1073-8.
9. Valero A, Herdman M, Bartra J, Ferrer M, Jáuregui I, Dávila IJ, del Cuvillo A, Montoro J, Mullol J, Sastre J, Canonica GW, Baiardini I. Adaptation and validation of the Spanish version of the chronic urticaria quality of life questionnaire (CU-Q2oL). J Investig Allergol Clin Immunol. 2008;18(6):426-32.
10. Jariwala SP, Moday H, de Asis L, Fodeman J, Hudes G, de Vos G, Rosenstreich D. The Urticaria Severity Score: a sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria. Ann Allergy Asthma Immunol. 2009;102:475-82.
11. Kobza Black A, Greaves MW. Antihistamines in urticaria and angioedema. In Simons FER, editors: Histamine and H1-antihistamines in allergic disease, 2nd Ed. Marcel Dekker, New York, 2002:249-83.
12. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197-201.
13. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol. 2006;30:47-51.
14. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004;114:465-74.
15. Kozel MMA, Sabroe RA. Chronic urticaria. Aetiology, management and current and future treatment options. Drugs. 2004;64:2515-36.
16. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol. 1989;84:66-71.
17. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. New Engl J Med. 1993;328:1599-604.
18. Sabroe RA, Grattan CE, Francis DM, Barr RM, Kobza BA, Greaves MW. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol. 1999;140:446-52.
19. Ferrer M, Kaplan AP. Chronic urticaria: What is new, where are we headed. Allergol et Immunopathol. 2007;35:57-61.
20. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol. 1999;104:169-72.
21. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Dermatol Venereol. 2007;87:196-205.
22. Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108:20-4.
23. Weller K Church MK, Kalogeromitros D, Krause K, Magerl M, Metz M, Pisarevskaja D, Siebenhaar F, Maurer M. Chronic spontaneous urticaria: how to assess quality of life in patients receiving treatment. Arch Dermatol. 2011;147:1221-3.
24. Mathias SD, Dreskin SC, Kaplan AP, Saini SS, Spector S, Rosén KE. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2010;105:142-8.
25. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc. 2006;27:96-
26. Sherman SA, Eisen S, Burwinkle TM, Varni JW. The PedsQL™ Present Functioning Visual Analogue Scales: preliminary reliability and validity. Health Qual Life Outcomes. 2006;4:75.
27. Izumi N, Mizuguchi H, Umehara H, Ogino S, Fukui H. Evaluation of efficacy and sedative profiles of H1 antihistamines by largescale surveillance using the visual analogue scale (VAS). Allergol Int. 2008;57:257-63.
28. Schipper H, Clinch J, Powell V. Definitions and conceptual issues. In Spilker B, edits. Quality of life assessment in clinical trials. New York: Raven Press, 1990:11-24.
29. Contreras Porta FJ, Martínez Donante A, Serrano Altamiras P, López Serrano MC. Calidad de vida en pacientes alérgicos. Alergol Immunol Clin. 2000;15:184-203.
30. Ware JE Jr., Sherbourne CD. The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection. Med Care. 1992;30:473-83.
31. Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, Braido F, Majani G, Canonica GW. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003;58:621-3.
32. Engin B, Uguz F, Yilmaz E, Ozdemir M, Mevlitoglu I. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol. 2008;22:36-40.
33. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.
34. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol. 2004;93:142-6.
35. Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol. 2006;97:419-28.
36. Grob JJ, Auquier P, Martin S, Lanon C, Bonerandi JJ. Development and validation of a quality of life measurement for chronic skin disorders in French: VQ-Dermato. Dermatology. 1999;199:213-22.
37. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152:289-95.
38. Jones-Caballero M, Peñas PF, García Díez A, Badía X, Chren MM. The Spanish version of Skindex-29. Int J Dermatol. 2000;39:907-12.
39. Maurer M, Ortonne J-P, Zuberbier T. Chronic urticaria: an internet survey on health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol. 2009;160:633-641.
40. Staubach P, Eckhardt-Henn A, Dechene M, Vonend A, Metz M, Magerl M, Breuer P, Maurer M. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154:294-8.
41. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol. 2000;43:24-30.
42. Mlynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, Brzoza Z, Kasperska-Zajac A, Rogala B, Zalewska-Janowska A, Zuberbier T, Maurer M: The German version of the chronic urticaria quality-of-life questionnaire: Factor analysis, validation, and initial clinical findings. Allergy. 2009;64:927-36.
43. Brzoza Z, Badura-Brzoza K, Mlynek A, Magerl M, Baiardini I, Canonica GW, Weller, K, Kocaturk E, Kalogeromitros D, Zalewska-Janowska A, Zuberbier T, Maurer M: Adaptation and initial results of the Polish version of the GA(2)LEN chronic urticaria quality of life questionnaire (CU-Q2oL). J Dermatol Sci. 2011;62:36-41.
44. Kocaturk E, Weller K, Martus P, Aktas S, Kavala M, Sarigul S, Baiardini I, Canonica GW, Brzoza Z, Kalogeromitros D, Maurer M. Turkish version of the chronic urticaria quality of life questionnaire: Cultural adaptation, assessment of reliability and validity. Acta Dermatovenereol. 2012;92:419-25.
45. Dias GA, PiresGV, Valle SO, Franca AT, Papi JA, Dortas SD, Jr., Levy SA, Baiardini I, Canonica GW. Cross-cultural adaptation of the brazilian-portuguese version of the chronic urticaria qualityof-life questionnaire-CU-Q2oL. Allergy. 2011;66:1487-93.
46. Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, Fokkens W, Gerthvan Wijk R, Giménez-Arnau A, Godse K, Grattan C, Grob JJ, La Grutta S, Kalogeromitros D, Kocatürk E, Lombardi C, Mota-Pinto A, Ridolo E, Saini SS, Sanchez-Borges M, Senna GE, Terreehorst I, TodoBom A, Toubi E, Bousquet J, Zuberbier T, Maurer M. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy. 2011;66:840-4.